Aarey Drugs & Pharmaceuticals Limited
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
0/10
|
0 | 14.68 | -100% | 18.46 | -100% |
| P/S |
|
0 | 0.8445 | -100% |
|
|
| P/BV |
|
0 | 2.31 | -100% |
|
|
| P/FCF |
|
0 | -137.64 | -100% |
|
|
| Ev/Ebitda |
|
0 | 8.55 | -100% |
|
|
| Ev/S |
|
0 | 0.9925 | -100% |
|
|
| Ev/FCF |
|
0 | -172.82 | -100% |
|
|
| E/P |
|
0 | 0.0699 | -100% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
0/10
|
0 | 11.48 | -100% | 2.39 | -100% |
| ROE |
|
0 | 17.24 | -100% |
|
|
| ROA |
|
0 | 8.43 | -100% |
|
|
| ROIC |
|
0 | 17.29 | -100% |
|
|
| ROS |
|
0 | 5.78 | -100% |
|
|
| ROCE |
|
0 | 24.92 | -100% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
10/10
|
0 | 1.35 | -100% | 1.34 | -100% |
| Nеt Debt/Ebitda |
|
0 | 1.3 | -100% |
|
|
| Debt/Ratio |
|
0 | 0.2107 | -100% |
|
|
| Debt/Equity |
|
0 | 0.9076 | -100% |
|
|
| Debt/Net Income |
|
0 | 2.66 | -100% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0/10
|
0 | 0.2278 | -100% | 0 | 0% |
| Number of years of dividend growth |
|
0 | 0.5 | -100% | ||
| DSI |
|
0 | 0.8571 | -100% |
|
|
| Average dividend growth |
|
0 | -406.14 | -100% |
|
|
| Average percentage for 5 years |
|
0 | 0.6911 | -100% |
|
|
| Average percentage for payments |
|
3.68 | 5.4 | -31.87% |
|
|
| Difference from average difference in sector |
|
-0.2278 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
3/10
|
16.79 | -60.13 | -127.92% | ||
| Growth impulse Ebitda in 5 years |
|
-13.85 | -59.83 | -76.85% | ||
| Growth impulse Net Income in 5 years |
|
-42.35 | -45.26 | -6.43% | ||
| Growth impulse FCF in 5 years |
|
331.06 | -101.69 | -425.56% | ||
| Growth impulse EPS in 5 years |
|
0 | 501.04 | -100% |
IP Score
3.04/10
